|
ADA, Washington 2006
WCC 2006, Barcelona
EASD 2006, Copenhagen/Malmoe
AHA 2006, Chicago
IDF 2006, Cape Town
ACC 2007, New Orleans
ADA, Washington 2006
A number of presentations of PROactive data were given at the American Diabetes Association (ADA) 66th Annual Scientific Sessions held in Washington DC, USA on 9–13 June 2006. They showed that, compared with placebo, long-term pioglitazone treatment given in addition to existing cardiovascular and glucose-lowering medication in patients with type 2 diabetes and macrovascular disease resulted in:
- Effects of Pioglitazone on Major Adverse Cardiovascular Events (MACE) and Myocardial Infarction: Results from PROactive
Authors: Wilcox & Kupfer
Compared with placebo, pioglitazone therapy resulted in clinically and statistically significant risk reductions in the time to major adverse cardiovascular events defined as cardiovascular death, non-fatal MI, or non-fatal stroke (18%) and time to fatal or non-fatal MI (23%).
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Long-term Pioglitazone Treatment Improves Markers of Liver Function: Results from PROactive
Authors: Heine, Schindhelm, Diamant
In the pioglitazone group, there was an overall shift toward normalisation from baseline in alanine aminotransferase (ALT), a marker of the amount of liver fat related to liver insulin resistance. A decrease of 5.9% in the occurrence of elevated ALT was noted in the pioglitazone group compared with a small increase in the placebo group (11.9%). This suggests that treatment with pioglitazone is associated with a lowering of liver fat content.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
Please click here to view the poster in PDF format
- Reduced Insulin Requirements and Improved Glycemic Control with Pioglitazone in Insulin-treated Patients with Type 2 Diabetes: Results from PROactive
Authors: Scheen & Charbonnel
In the one-third of patients in PROactive who were treated with insulin at baseline, pioglitazone provided sustained glycaemic control. Insulin was discontinued in 9% of patients in the pioglitazone group compared with 2% in the placebo group, and there was a lower mean insulin dose in the pioglitazone group at final visit (42 U/day versus 55 U/day).
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Pioglitazone in Triple Oral Therapy: Long-term Glycemic Results from PROactive
Authors: Charbonnel & Scheen
Increasing treatment from a dual therapy regimen (metformin plus sulfonylurea) to a triple therapy regimen by adding pioglitazone resulted in sustained glycaemic control and a reduced need for insulin. In the piogitazone group, 16% had either metformin or sulfonylurea dropped from their regimen (versus 8% in the placebo group), while 16% had insulin added (versus 31% in the placebo group).
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Pioglitazone Delays the Need for Permanent Insulin Use: Results from PROactive
Authors: Massi-Benedetti, Scheen, Charbonnel
Double the number of placebo-treated patients (n=362) progressed to permanent insulin use versus pioglitazone-treated patients (n=183). This 50% reduction in progression to permanent insulin use was irrespective of baseline glucose-lowering treatment.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
WCC 2006, Barcelona
Two poster presentations and two oral presentations of PROactive data were given at the World Congress of Cardiology (a joint meeting of the European Society of Cardiology
and the World Heart Federation) held 2–6 September, 2006 in Barcelona, Spain
EASD 2006, Copenhagen/Malmoe
Five poster presentations and three oral presentations of PROactive data were given at the 42nd Annual Meeting of the European Association for the Study of Diabetes held 14–17 September, 2006 in Copenhagen/Malmoe, Denmark/Sweden
- Diamant, Schindhelm, Heine. Long-term treatment with pioglitazone improves markers of liver function in patients with type 2 diabetes: Results from PROactive. Oral presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Wilcox. An analysis from PROactive on the effects of pioglitazone on major adverse cardiovascular events (MACE) and myocardial infarction. Oral presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Spanheimer, Tan, Yates. The effects of long-term pioglitazone therapy on lipid profiles in high-risk type 2 diabetes patients: Results from PROactive. Oral presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Charbonnel, Scheen. Long-term glycaemic effects of pioglitazone in triple oral therapy: Results from PROactive. Poster presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Schmitz, Scheen, Charbonnel. Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: Results from PROactive. Poster presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
- Erdmann, Charbonnel, Dormandy, Yates, Wilcox, Massi-Benedetti. Pioglitazone treatment in patients with type 2 diabetes and a history of MI: Subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Poster presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
Please click here to view the poster in PDF format.
- Dormandy J, Bousser M-G, Wilcox R. Pioglitazone in patients with or without a history of stroke: Results from PROactive. Oral presentation.
Please click here to download the abstract in Word format.
Please click here to view the abstract in PDF format.
AHA 2006, Chicago
Two poster presentations of PROactive data were given at the American Heart Association Scientific Sessions 2006 held 12–15 November, 2006 in Chicago, USA
IDF 2006, Cape Town
Four poster presentations of PROactive data were given at the International Diabetes Federation 19th World Diabetes Congress held 3–7 December 2006 in Cape Town, South Africa from 2006
ACC 2007, New Orleans
One poster presentation of PROactive data was given at the American College of Cardiology Annual Scientific Session held 24–28 March 2007 in New Orleans, LA, USA
|
